MG
NAMS icon

Mather Group’s NewAmsterdam Pharma NAMS Stock Holding History

Mather Group’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$28.4K – 1285
2025
Q3 		$28.4K Buy
+1,000
New +$24K ﹤0.01% 1038

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Mather Group's NAMS Position: Q4 2025 in Review

Mather Group sold out of NewAmsterdam Pharma (NAMS) in Q4 2025, closing a stake of 1,000 shares — an estimated $28.4K sold.

Mather Group first reported a position in NAMS in Q3 2025 and held it in 1 quarter. The position peaked at $28.4K in Q3 2025. 186 funds tracked by Wall St. Rank hold NAMS as of Q4 2025.

  • Mather Group reported no remaining NewAmsterdam Pharma position as of Q4 2025 after selling out during the quarter.
  • Mather Group sold 1,000 NewAmsterdam Pharma shares in Q4 2025, an estimated $28.4K.
  • Mather Group first reported a position in NewAmsterdam Pharma in Q3 2025 and held it in 1 quarter.
  • Mather Group's NewAmsterdam Pharma position peaked at $28.4K in Q3 2025.
  • 186 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2025.

Based on Mather Group's 13F filing for Q4 2025, filed 13 Jan 2026.